Editas Medicine
EDIT
312 hedge funds and large institutions have $3.72B invested in Editas Medicine in 2020 Q4 according to their latest regulatory filings, with 105 funds opening new positions, 87 increasing their positions, 69 reducing their positions, and 31 closing their positions.
239% more first-time investments, than exits
New positions opened: 105 | Existing positions closed: 31
140% more capital invested
Capital invested by funds: $1.55B → $3.72B (+$2.17B)
40% more call options, than puts
Call options by funds: $188M | Put options by funds: $134M
31% more funds holding
Funds holding: 239 → 312 (+73)
26% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 69
3.55% less ownership
Funds ownership: 88.57% → 85.01% (-3.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$16.8M |
| 2 |
Voloridge Investment Management
Jupiter,
Florida
|
+$16.7M |
| 3 |
GLA
Great Lakes Advisors
Chicago,
Illinois
|
+$15.6M |
| 4 |
SOMRS
State of Michigan Retirement System
Lansing,
Michigan
|
+$12.6M |
| 5 |
JP Morgan Chase
New York
|
+$5.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAMA
Nikko Asset Management Americas
New York
|
-$28.2M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$28.2M |
| 3 |
State Street
Boston,
Massachusetts
|
-$26.4M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$22.4M |
| 5 |
DM
Deerfield Management
New York
|
-$18.5M |
EDIT Hedge Fund Activity: Q4 2020 in Review
312 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q4 2020, worth a combined $3.72B — up 140% from $1.55B a quarter earlier.
Buyers outnumbered sellers: 105 funds opened new EDIT positions and 31 closed out — a net gain of 74 holders — while 87 added to existing stakes and 69 trimmed.
The largest buyer was D.E. Shaw & Co, adding an estimated $16.8M. The largest seller was Nikko Asset Management Americas, cutting an estimated $28.2M.
- 312 institutional investors held Editas Medicine (EDIT) as of Q4 2020, up from 239 in Q3 2020.
- Funds reported $3.72B of Editas Medicine stock for Q4 2020, up 140% quarter-over-quarter.
- 105 funds opened new Editas Medicine positions in Q4 2020 and 31 closed out, a net change of +74 holders.
- The largest Editas Medicine buyer in Q4 2020 was D.E. Shaw & Co, an estimated $16.8M added.
- The largest Editas Medicine seller in Q4 2020 was Nikko Asset Management Americas, an estimated $28.2M sold.
Based on aggregated 13F filings for Q4 2020.